nisoldipine has been researched along with Myocardial Ischemia in 31 studies
Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.
nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.
methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined whether nisoldipine, a calcium (Ca) channel blocker, increases coronary blood flow (CBF) without decreasing aortic blood pressure (AoP) with ischemic and nonischemic hearts, and whether the presence of cellular acidosis in ischemic myocardium contributes to the augmentation of coronary vasodilation due to nisoldipine." | 7.70 | Nisoldipine selectively induces coronary vasodilation and improves mild myocardial ischemia in dogs: a potential role of cellular acidosis. ( Funaya, H; Hori, M; Kitakaze, M; Komamura, K; Kuzuya, T; Minamino, T; Mori, H; Node, K; Takeda, H, 1998) |
| " Dopamine dosage in the N group on postoperative day 1 was lower than in controls (5." | 6.69 | Protective effect of nisoldipine on myocardial ischemia during coronary bypass surgery. ( Hibi, M; Kawamura, M; Murakami, F; Nakayama, R; Oshima, H; Usui, A; Yoshida, K, 1999) |
| " This trial confirms that immediate-release nisoldipine when added to existent beta-blocker therapy is an active antianginal and anti-ischemic agent, but that the immediate-release formulation loses its antianginal effect at the end of its dosing interval (9 to 14 hours)." | 6.67 | Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris. ( Bittar, N; Glasser, SP; Katz, R; Labreche, DG; Schulman, P; Singh, B, 1994) |
| "To compare the negative inotropic effects of the four dihydropyridine-calcium-channel-blockers nifedipine (NIF), isradipine (ISR), nisoldipine (NIS) and felodipine (FEL) in man, the drugs were infused within 30 min intravenously in an equihypotensive dosage (NIF 2 mg, ISR 0." | 6.67 | [Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease]. ( Ickrath, O; Karsch, KR; Mauser, M; Voelker, W, 1993) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 6.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine is a dihydropyridine calcium entry blocker that inhibits contraction of vascular smooth muscle with a potency that is 2-3 times greater than its impact on myocardial contractility." | 6.39 | Why is nisoldipine a specific agent in ischemic left ventricular dysfunction? ( Knorr, AM, 1995) |
| "Nisoldipine treatment can protect from dipyridamole-induced ischaemia, being associated with a longer stress time, and completely preventing the development of ischaemia in some patients." | 5.30 | Protective effect of nisoldipine on dipyridamole-induced myocardial ischemia: correlation with exercise electrocardiography. ( Lattanzi, F; Levantesi, D; Lucarini, AR; Orsini, E; Paci, AM; Paperini, L; Reisenhofer, B; Squarcini, G; Topi, A, 1998) |
| "The aim of this study was to investigate the anti-ischemic and antianginal activity and the duration of the new dihydropyridine calcium blocker nisoldipine (NIS) in patients with stable angina pectoris." | 5.07 | Effect of calcium antagonists on exercise tests. ( Cherchi, A; Cherchi, PA; Lai, C; Lai, G; Onnis, E; Solinas, R, 1992) |
| "We examined whether nisoldipine, a calcium (Ca) channel blocker, increases coronary blood flow (CBF) without decreasing aortic blood pressure (AoP) with ischemic and nonischemic hearts, and whether the presence of cellular acidosis in ischemic myocardium contributes to the augmentation of coronary vasodilation due to nisoldipine." | 3.70 | Nisoldipine selectively induces coronary vasodilation and improves mild myocardial ischemia in dogs: a potential role of cellular acidosis. ( Funaya, H; Hori, M; Kitakaze, M; Komamura, K; Kuzuya, T; Minamino, T; Mori, H; Node, K; Takeda, H, 1998) |
| "To investigate the clinical applicability of the three-dimensional (3D) myocardial imaging using a newly developed system (the Application Visualization System-Medical Viewer), thallium-201 myocardial single photon emission computed tomography was performed in 19 patients with previous myocardial infarction before and after treatment with nisoldipine." | 3.69 | Clinical application of three-dimensional myocardial imaging: evaluation of efficacy of medical treatment on myocardial perfusion. ( Hosoi, H; Ishiguro, S; Morishita, T; Muto, H; Sugita, J; Takahashi, M; Takano, M; Yamashina, H; Yamazaki, J, 1996) |
| " Dopamine dosage in the N group on postoperative day 1 was lower than in controls (5." | 2.69 | Protective effect of nisoldipine on myocardial ischemia during coronary bypass surgery. ( Hibi, M; Kawamura, M; Murakami, F; Nakayama, R; Oshima, H; Usui, A; Yoshida, K, 1999) |
| " This trial confirms that immediate-release nisoldipine when added to existent beta-blocker therapy is an active antianginal and anti-ischemic agent, but that the immediate-release formulation loses its antianginal effect at the end of its dosing interval (9 to 14 hours)." | 2.67 | Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris. ( Bittar, N; Glasser, SP; Katz, R; Labreche, DG; Schulman, P; Singh, B, 1994) |
| "To compare the negative inotropic effects of the four dihydropyridine-calcium-channel-blockers nifedipine (NIF), isradipine (ISR), nisoldipine (NIS) and felodipine (FEL) in man, the drugs were infused within 30 min intravenously in an equihypotensive dosage (NIF 2 mg, ISR 0." | 2.67 | [Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease]. ( Ickrath, O; Karsch, KR; Mauser, M; Voelker, W, 1993) |
| "Nisoldipine is a second-generation dihydropyridine calcium channel blocker (CCB)." | 2.40 | Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease. ( Fodor, JG, 1997) |
| "Nisoldipine coat-core is an extended-release once-daily formulation of a dihydropyridine calcium antagonist effective in the treatment of chronic stable angina pectoris." | 2.40 | Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease. ( Langtry, HD; Spencer, CM, 1997) |
| "Nisoldipine is a dihydropyridine calcium entry blocker that inhibits contraction of vascular smooth muscle with a potency that is 2-3 times greater than its impact on myocardial contractility." | 2.39 | Why is nisoldipine a specific agent in ischemic left ventricular dysfunction? ( Knorr, AM, 1995) |
| "Nisoldipine treatment can protect from dipyridamole-induced ischaemia, being associated with a longer stress time, and completely preventing the development of ischaemia in some patients." | 1.30 | Protective effect of nisoldipine on dipyridamole-induced myocardial ischemia: correlation with exercise electrocardiography. ( Lattanzi, F; Levantesi, D; Lucarini, AR; Orsini, E; Paci, AM; Paperini, L; Reisenhofer, B; Squarcini, G; Topi, A, 1998) |
| " First, dose-response curves were constructed; from these data the EC50 concentration for the three calcium antagonists was calculated." | 1.29 | Hemodynamic and antiischemic effects of nifedipine, lacidipine, and nisoldipine in rat isolated working heart. ( Pfaffendorf, M; Pijl, AJ; van Zwieten, PA, 1993) |
| "Nisoldipine was administered to the hearts before 60 minutes of global ischemia." | 1.29 | Improvement of ischemic myocardial dysfunction by nisoldipine. ( Itakura, A; Saida, K; Umeda, M, 1994) |
| "Nisoldipine did not produce any beneficial effect without the inhibition of the increase in end-diastolic pressure during ischemia nor did it do so without the increase of reperfusion flow." | 1.29 | Improvement of ischemic myocardial dysfunction by nisoldipine in relation to its coronary vasodilating action. ( Saida, K; Umeda, M, 1993) |
| "Nisoldipine has a beneficial effect on regional diastolic function during ischaemia and reperfusion by decreasing regional wall stiffness and preventing diastolic thinning of the ischaemic wall." | 1.29 | Regional diastolic dysfunction in postischaemic myocardium in calf: effect of nisoldipine. ( Grimm, J; Hess, OM; Jacob, M; Krogmann, ON; Leskosek, B; Pasic, M; Tjon-A-Meeuw, L; von Segesser, L, 1993) |
| "Treatment with nisoldipine prevented the detrimental impact of ischemic heart disease to an extent that all measured parameters in CANN rats were found to be intermediate between unoperated controls and CANW animals." | 1.29 | Nisoldipine improves ventricular function in rats with ischemic heart failure. ( Capasso, JM, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 31 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pijl, AJ | 1 |
| Pfaffendorf, M | 1 |
| van Zwieten, PA | 1 |
| Tamburrini, LR | 1 |
| Knorr, AM | 1 |
| Nohara, R | 1 |
| Hata, T | 1 |
| Hosokawa, R | 1 |
| Lee, L | 1 |
| Fujita, M | 1 |
| Kambara, H | 1 |
| Sasayama, S | 1 |
| Glasser, SP | 2 |
| Bittar, N | 2 |
| Labreche, DG | 1 |
| Singh, B | 1 |
| Katz, R | 1 |
| Schulman, P | 1 |
| Rousseau, MF | 2 |
| Melin, J | 1 |
| Benedict, CR | 1 |
| Ahn, S | 1 |
| Raphaël, D | 1 |
| Bornemann, M | 1 |
| Pouleur, H | 2 |
| Saida, K | 2 |
| Umeda, M | 2 |
| Itakura, A | 1 |
| Grönefeld, G | 1 |
| Bernhardt, J | 1 |
| Schneider, W | 1 |
| Baumgart, D | 1 |
| Ehring, T | 3 |
| Heusch, G | 3 |
| Sheiban, I | 1 |
| Tonni, S | 1 |
| Benussi, P | 1 |
| Marini, A | 1 |
| Trevi, GP | 1 |
| Mauser, M | 1 |
| Voelker, W | 1 |
| Ickrath, O | 1 |
| Karsch, KR | 1 |
| Krogmann, ON | 1 |
| Tjon-A-Meeuw, L | 1 |
| Hess, OM | 1 |
| Jacob, M | 1 |
| Grimm, J | 1 |
| Leskosek, B | 1 |
| Pasic, M | 1 |
| von Segesser, L | 1 |
| Ripa, S | 1 |
| Garland, WT | 1 |
| Weiss, R | 1 |
| Nademanee, K | 1 |
| Singh, S | 1 |
| Capasso, JM | 1 |
| Yamazaki, J | 1 |
| Hosoi, H | 1 |
| Ishiguro, S | 1 |
| Muto, H | 1 |
| Yamashina, H | 1 |
| Morishita, T | 1 |
| Takano, M | 1 |
| Sugita, J | 1 |
| Takahashi, M | 1 |
| Melcher, A | 1 |
| Dens, J | 1 |
| Curry, P | 1 |
| Hagel, H | 1 |
| Fodor, JG | 1 |
| Langtry, HD | 1 |
| Spencer, CM | 1 |
| Lattanzi, F | 1 |
| Paperini, L | 1 |
| Orsini, E | 1 |
| Paci, AM | 1 |
| Levantesi, D | 1 |
| Topi, A | 1 |
| Reisenhofer, B | 1 |
| Lucarini, AR | 1 |
| Squarcini, G | 1 |
| Gheorghiade, M | 1 |
| Köppel, H | 1 |
| Gasser, R | 1 |
| Pokan, R | 2 |
| Willomitzer, R | 1 |
| Cichocki, L | 1 |
| Pilger, E | 1 |
| Klein, W | 2 |
| Kitakaze, M | 1 |
| Funaya, H | 1 |
| Komamura, K | 1 |
| Node, K | 1 |
| Minamino, T | 1 |
| Mori, H | 1 |
| Takeda, H | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Usui, A | 1 |
| Kawamura, M | 1 |
| Murakami, F | 1 |
| Oshima, H | 1 |
| Yoshida, K | 1 |
| Hibi, M | 1 |
| Nakayama, R | 1 |
| Amende, I | 1 |
| Bentivegna, L | 1 |
| Morgan, JP | 1 |
| Lai, C | 1 |
| Cherchi, A | 1 |
| Onnis, E | 1 |
| Solinas, R | 1 |
| Lai, G | 1 |
| Cherchi, PA | 1 |
| Eber, B | 1 |
| Schumacher, M | 1 |
| Zweiker, R | 1 |
| Böhm, M | 1 |
7 reviews available for nisoldipine and Myocardial Ischemia
| Article | Year |
|---|---|
Why is nisoldipine a specific agent in ischemic left ventricular dysfunction?
Topics: Animals; Coronary Vessels; Depression, Chemical; Guinea Pigs; Heart; Membrane Potentials; Muscle, Sm | 1995 |
Nisoldipine in severe ischaemic left ventricular dysfunction.
Topics: Coronary Circulation; Diastole; Hemodynamics; Humans; Myocardial Ischemia; Nisoldipine; Ventricular | 1993 |
Nisoldipine CC: clinical experience in ischaemic heart disease.
Topics: Amlodipine; Calcium Channel Blockers; Delayed-Action Preparations; Diltiazem; Double-Blind Method; H | 1997 |
Dihydropyridine calcium antagonists: beneficial or adverse effects in the setting of myocardial ischaemia/reperfusion?
Topics: Animals; Calcium Channel Blockers; Coronary Circulation; Coronary Vessels; Dihydropyridines; Dogs; H | 1997 |
Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.
Topics: Aging; Angina Pectoris; Antihypertensive Agents; Blood Pressure; Calcium Channel Blockers; Delayed-A | 1997 |
Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.
Topics: Calcium Channel Blockers; Delayed-Action Preparations; Drug Interactions; Food-Drug Interactions; Hu | 1997 |
[Nisoldipine in comparison with long-term nitrates].
Topics: Angina Pectoris; Animals; Coronary Circulation; Coronary Disease; Coronary Vasospasm; Humans; Myocar | 1992 |
10 trials available for nisoldipine and Myocardial Ischemia
| Article | Year |
|---|---|
[Nisoldipine in the treatment of ischemic cardiopathy in the aged. Study of electric systole].
Topics: Aged; Calcium Channel Blockers; Dose-Response Relationship, Drug; Electrocardiography; Female; Human | 1995 |
Effects of nisoldipine in silent myocardial ischemia after healing of acute myocardial infarction.
Topics: Adult; Aged; Dipyridamole; Exercise Tolerance; Female; Hemodynamics; Humans; Male; Middle Aged; Myoc | 1995 |
Antianginal and anti-ischemic efficacy of immediate-release nisoldipine in chronic stable angina pectoris.
Topics: Adrenergic beta-Antagonists; Adult; Angina Pectoris; Blood Pressure; Chronic Disease; Double-Blind M | 1994 |
Effects of nisoldipine therapy on myocardial perfusion and neuro-hormonal status in patients with severe ischaemic left ventricular dysfunction.
Topics: Arginine Vasopressin; Atrial Natriuretic Factor; Coronary Circulation; Double-Blind Method; Echocard | 1994 |
[Dose-response relationship of nisoldipine in patients with stable angina pectoris and stress-induced myocardial ischemia].
Topics: Adult; Aged; Angina Pectoris; Cardiac Catheterization; Coronary Disease; Delayed-Action Preparations | 1993 |
Left ventricular dysfunction following transient ischaemia induced by transluminal coronary angioplasty. Beneficial effects of calcium antagonists against post-ischaemic myocardial stunning.
Topics: Adult; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Coronary Circulation; Coronary Disease | 1993 |
[Comparison of the cardiodepressive effects of nifedipine, isradipine, nisoldipine and felodipine in patients with coronary heart disease].
Topics: Adult; Aged; Calcium Channel Blockers; Coronary Disease; Electrocardiography; Exercise Test; Felodip | 1993 |
Antianginal and antiischemic efficacy of monotherapy extended-release nisoldipine (Coat Core) in chronic stable angina.
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Calcium Channel Blockers; Chronic Disease; Delayed- | 1995 |
Protective effect of nisoldipine on myocardial ischemia during coronary bypass surgery.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Coronary Artery Bypass; Coronary Circulation; | 1999 |
Effect of calcium antagonists on exercise tests.
Topics: Adult; Aged; Analysis of Variance; Angina Pectoris; Blood Pressure; Double-Blind Method; Electrocard | 1992 |
14 other studies available for nisoldipine and Myocardial Ischemia
| Article | Year |
|---|---|
Hemodynamic and antiischemic effects of nifedipine, lacidipine, and nisoldipine in rat isolated working heart.
Topics: Animals; Calcium Channel Blockers; Cardiac Output; Coronary Circulation; Dihydropyridines; Dose-Resp | 1993 |
Improvement of ischemic myocardial dysfunction by nisoldipine.
Topics: Animals; Coronary Vessels; Disease Models, Animal; Heart; Heart Rate; L-Lactate Dehydrogenase; Male; | 1994 |
A proischaemic action of nisoldipine: relationship to a decrease in perfusion pressure and comparison to dipyridamole.
Topics: Animals; Blood Pressure; Dipyridamole; Dogs; Heart; Myocardial Contraction; Myocardial Ischemia; Nis | 1993 |
Improvement of ischemic myocardial dysfunction by nisoldipine in relation to its coronary vasodilating action.
Topics: Animals; Blood Pressure; Coronary Circulation; Diltiazem; Heart Rate; In Vitro Techniques; Male; Myo | 1993 |
Regional diastolic dysfunction in postischaemic myocardium in calf: effect of nisoldipine.
Topics: Animals; Blood Flow Velocity; Blood Pressure; Cattle; Coronary Circulation; Diastole; Heart Rate; My | 1993 |
Nisoldipine improves ventricular function in rats with ischemic heart failure.
Topics: Animals; Body Weight; Calcium; Calcium Channel Blockers; Coronary Vessels; Hemodynamics; Male; Myoca | 1995 |
Clinical application of three-dimensional myocardial imaging: evaluation of efficacy of medical treatment on myocardial perfusion.
Topics: Aged; Calcium Channel Blockers; Coronary Circulation; Exercise Test; Female; Heart; Humans; Image Pr | 1996 |
Protective effect of nisoldipine on dipyridamole-induced myocardial ischemia: correlation with exercise electrocardiography.
Topics: Calcium Channel Blockers; Coronary Angiography; Dipyridamole; Echocardiography; Electrocardiography; | 1998 |
Nisoldipine and myocardial infarction.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Myocardial Ischemia; Nisoldipine | 1998 |
[Protection against myocardial ischemia by nisoldipine--an experimental study with valinomycin K-sensitive microelectrodes].
Topics: Animals; Calcium Channel Blockers; Culture Techniques; Electrocardiography; Guinea Pigs; Microelectr | 1998 |
Nisoldipine selectively induces coronary vasodilation and improves mild myocardial ischemia in dogs: a potential role of cellular acidosis.
Topics: Acidosis; Amiloride; Animals; Bicarbonates; Blood Pressure; Buffers; Coronary Circulation; Diuretics | 1998 |
New aspects of the treatment of ischemic heath disease with calcium antagonists. Proceedings of the International Nisoldipine Symposium. Düsseldorf, Germany, March 27-29, 1992.
Topics: Animals; Calcium Channel Blockers; Humans; Myocardial Ischemia; Nisoldipine | 1992 |
Ventricular function and calcium handling during ischemia.
Topics: Animals; Calcium; Ferrets; Myocardial Contraction; Myocardial Ischemia; Myocardial Reperfusion; Niso | 1992 |
The calcium antagonist nisoldipine improves the functional recovery of reperfused myocardium only when given before ischemia.
Topics: Analysis of Variance; Animals; Calcium; Coronary Circulation; Dogs; Myocardial Ischemia; Myocardial | 1992 |